Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy? (original) (raw)

• Druker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, **355:**2408–2417.
  Article PubMed CAS Google Scholar
• O’Brien SG, Guilhot F, Goldman J, et al.: International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood 2008, **112:**186.
  Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, **348:**994–1004.
  Article PubMed Google Scholar
• Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, **349:**1423–1432.
  Article PubMed CAS Google Scholar
• Cortes J, Talpaz M, O’Brien S, et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, **11:**3425–3432.
  Article PubMed CAS Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al.: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intentionto-treat analysis. J Clin Oncol 2008, **26:**3358–3363.
  Article PubMed Google Scholar
• Quintás-Cardama A, Kantarjian HM, Cortes JE: Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, **16:**122–131.
  PubMed Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, et al.: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, **7:**345–356.
  Article PubMed CAS Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, **111:**4022–4028.
  Article PubMed CAS Google Scholar
• Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, **109:**3496–3499.
  Article PubMed CAS Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, **344:**1038–1042.
  Article PubMed CAS Google Scholar
• Branford S, Rudzki Z, Harper A, et al.: Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, **17:**2401–2409.
  Article PubMed CAS Google Scholar
• Kantarjian H, O’Brien S, Shan J, et al.: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008, **112:**837–845.
  Article PubMed Google Scholar
• Quintás-Cardama A, Kantarjian H, Cortes J: Tyrosine kinase inhibitors for chronic myelogenous leukemia. New Engl J Med 2007, **357:**1557; author reply 1558.
  PubMed Google Scholar
• Kantarjian H, Talpaz M, O’Brien S, et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, **103:**2873–2878.
  Article PubMed CAS Google Scholar
• Cortes J, Giles F, O’Brien S, et al.: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003, **102:**83–86.
  Article PubMed CAS Google Scholar
• Hughes TP, Branford S, White DL, et al.: Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008, **112:**3965–3973.
  Article PubMed CAS Google Scholar
• Cortes J, Baccarani M, Guilhot F, et al.: A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood 2008, **112:**335.
  Google Scholar
• Baccarani M, Castagnetti F, Simonsson B, et al.: Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of an European Leukemianet prospective study comparing 400 mg and 800 mg front-line [abstract]. Blood 2008, **112:**185.
  Google Scholar
• Jabbour E, Kantarjian HM, Jones D, et al.: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, **113:**2154–2160.
  Article PubMed CAS Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al.: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, **47:**6658–6661.
  Article PubMed CAS Google Scholar
• Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, **305:**399–401.
  Article PubMed CAS Google Scholar
• O’Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, **65:**4500–4505.
  Article PubMed Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, **354:**2531–2541.
  Article PubMed CAS Google Scholar
• Mauro M, Baccarani M, Cervantes F, et al.: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008, **26(May 20 Suppl):**7009.
  Google Scholar
• Rousselot P, Facon T, Paquette R, et al.: Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standarddose imatinib: 2-year follow-up data from START-R [abstract]. J Clin Oncol 2008, **26(May 20 Suppl):**7012.
  Google Scholar
• Shah N, Kim DW, Kantarjian H, et al.: Dasatinib doseoptimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose [abstract]. Blood 2008, **112:**3225.
  Google Scholar
• Kantarjian H, Kim DW, Dorlhiac-Llacer P, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with accelerated phase chronic myeloid leukemia: 2-year follow-up data from CA180-035 [abstract]. Blood 2008, **112:**3224.
  Google Scholar
• Saglio G, Kantarjian H, Hochhaus A, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with chronic myeloid leukemia in blast phase: 2-year data from CA180-035 [abstract]. Blood 2008, **112:**3226.
  Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, **7:**129–141.
  Article PubMed CAS Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, **354:**2542–2551.
  Article PubMed Google Scholar
• Kantarjian H, Giles F, Bhalla K, et al.: Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, **112:**3238.
  Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, **110:**3540–3546.
  Article PubMed CAS Google Scholar
• Le Coutre P, Giles F, Hochhaus A, et al.: Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, **112:**3229.
  Google Scholar
• Giles F, Larson RA, Kantarjian K, et al.: Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. Blood 2007, **110:**1025.
  Article Google Scholar
• Remsing Rix LL, Rix U, Colinge J, et al.: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009, **23:**477–485.
  Article PubMed CAS Google Scholar
• Redaelli S, Piazza R, Rostagno R, et al.: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, **27:**469–471.
  Article PubMed CAS Google Scholar
• Cortes J, Kantarjian H, Kim DW, et al.: Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood 2008, **112:**1098.
  Google Scholar
• Gambacorti-Passerini C, Pogliani E, Baccarani M, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood 2008, **112:**1101.
  Article Google Scholar
• Rosti G, Castagnetti F, Poerio A, et al.: High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. Blood 2008, **112:**181.
  Google Scholar
• Cortes J, O’Brien S, Borthakur G, et al.: Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CMLCP) [abstract]. Blood 2008, **112:**182.
  Google Scholar
• Cortes J, O’Brien S, Jones D, et al.: Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood 2008, **112:**446.
  Google Scholar
• Quintás-Cardama A, Kantarjian H, Jones D, et al.: Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, **109:**497–499.
  Article PubMed Google Scholar
• Giles F, Le Coutre P, Bhalla K, et al.: Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study [abstract]. Blood 2008, **112:**3234.
  Article Google Scholar
• Garg RJ, Kantarjian H, O’Brien SM, et al.: The use of 2nd generation tyrosine kinase inhibitors (TKI) after failure to 2 prior TKI: long-term follow-up [abstract]. Blood 2008, **112:**2119.
  Google Scholar
• Kozopas KM, Yang T, Buchan HL, et al.: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 1993, **90:**3516–3520.
  Article PubMed CAS Google Scholar
• Chen Y, Hu Y, Michaels S, et al.: Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood 2007, **110:**2912.
  Google Scholar
• Quintás-Cardama A, Kantarjian H, Garcia-Manero G, et al.: Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007, **109:**248–255.
  Article PubMed Google Scholar
• Cortes J, Khoury HJ, Corm S, et al.: Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation—results of an ongoing multicenter phase II study [abstract]. Blood 2008, **112:**3239.
  Google Scholar
• Cortes J, Paquette R, Talpaz M, et al.: Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/Aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood 2008, **112:**3232.
  Google Scholar
• Paquette R, Shah N, Sawyers C, et al.: PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]. Blood 2007, **110:**1030.
  Google Scholar
• O’Hare T, Eide CA, Adrian LT, et al.: Complete suppression of in vitro resistance by AP24534, a pan-BCR-ABL inhibitor [abstract]. Blood 2008, **112:**726.
  Google Scholar
• Van Etten RA, Chan WW, Zaleskas VM, et al.: Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood 2008, **112:**576.
  Article Google Scholar